Skip to content

Dr. Gearóid Tuohy

An international consortium have presented “THE FIGHT INHERITED RETINAL BLINDNESS! PROJECT” –  a new treatment outcome and natural history registry for inherited retinal disease (IRD).

A consortium of researchers from Australia, New Zealand, USA, UK and Switzerland, have published paper for a new treatment outcome and natural history registry for… Read More »An international consortium have presented “THE FIGHT INHERITED RETINAL BLINDNESS! PROJECT” –  a new treatment outcome and natural history registry for inherited retinal disease (IRD).

A review of fundus autofluorescence (FAF) underscores an indispensable technology for the diagnosis, monitoring and outcome measures of numerous retinal diseases.

Researchers at the Department of Ophthalmology, Vagelos College of Physicians and Surgeons, Columbia University, New York, have published a study outlining how fundus autofluorescence (FAF)… Read More »A review of fundus autofluorescence (FAF) underscores an indispensable technology for the diagnosis, monitoring and outcome measures of numerous retinal diseases.

A small study of severe variants of ABCA4 reports a new genotype–phenotype correlation with Early-Onset Severe Retinal Dystrophy (EOSRD).

Researchers at the Department of Human Genetics, Radboud University Medical Centre, Nijmegen, the Netherlands, have reported a limited study for three probands showing that biallelic… Read More »A small study of severe variants of ABCA4 reports a new genotype–phenotype correlation with Early-Onset Severe Retinal Dystrophy (EOSRD).

Clinical study of >3,500 IRD patients reports novel genotype-phenotype associations using optical coherence tomography (OCT) imaging.  

Clinical researchers at the Institute of Ophthalmology, University College London, UK, and Moorfields Eye Hospital NHS Foundation Trust, London, have presented a novel deep learning… Read More »Clinical study of >3,500 IRD patients reports novel genotype-phenotype associations using optical coherence tomography (OCT) imaging.  

Beacon Therapeutics announce the completion of enrolment for the Phase 2/3 trial for “laru-zova”, for the treatment of XLRP.

Beacon Therapeutics Holdings Limited, based in London, UK and Cambridge, Massachusetts, have announced the completion of enrolment in its registrational Phase 2/3 VISTA trial evaluating… Read More »Beacon Therapeutics announce the completion of enrolment for the Phase 2/3 trial for “laru-zova”, for the treatment of XLRP.